Psychedelic Safety: Why Screening and Follow-Up Matter

Psychedelic safety is not a simple choice between 'harmless' and 'dangerous.' Risk depends on the substance, a person's health, other medicines, the setting, and the support available afterward. Findings from carefully screened research participants should not be treated as a safety guarantee for everyone.

Screening is part of the intervention

Trials commonly assess cardiovascular health, psychiatric history, current symptoms, substance use, and medications. Some exclude people with histories or conditions that could increase risk. Those exclusions protect participants but also create gaps in the evidence: a study cannot establish safety in groups it did not include.

A history of mania or psychosis deserves particular attention. So do pregnancy, unstable medical illness, and suicidal symptoms. Screening should be a genuine clinical assessment, not a sales questionnaire designed to approve nearly every applicant. A responsible provider explains why a service might be unsuitable.

Physical and psychological effects both count

A 2024 JAMA Network Open review of six psilocybin trials found increased risks of several acute effects, including nausea, headache, anxiety, dizziness, and elevated blood pressure. Most reported effects resolved within 48 hours. That finding concerns short-term outcomes in monitored studies, not proof that all possible harms are brief.

Fear, confusion, or overwhelming emotions can be distressing even without a medical emergency. Intense experiences are not automatically healing. Support should respect a person's dignity and preferences, with clear procedures for escalating care when distress or physical symptoms become concerning.

Medication review is essential

Interactions vary across psilocybin, LSD, MDMA, ketamine, and other substances. A general online checklist cannot replace an individualized review by a qualified clinician. Include prescriptions, nonprescription medicines, supplements, alcohol, and other drug use when discussing potential risks.

Do not abruptly stop medication to pursue psychedelic treatment or meet a study's eligibility requirements. Withdrawal and recurrence of the underlying illness can themselves be dangerous. If a research protocol requires medication changes, ask who supervises them and how symptoms will be monitored.

Look beyond the session

Useful questions include who stays with participants, what medical equipment and emergency arrangements exist, how unwanted touch is prevented, and how complaints are handled. Consent should be specific and ongoing. Psychological vulnerability is never permission for sexual contact, coercion, or pressure to accept a therapist's interpretation.

Follow-up matters because problems can emerge after leaving a clinic or service center. Ask how to obtain help for persistent insomnia, worsening mood, unusual perceptions, or impaired functioning. Clinical trial monitoring, state-licensed services, and commercial wellness programs are different systems with different safeguards. Neither legality nor a reassuring atmosphere establishes medical effectiveness. Seek emergency care for immediate danger, severe confusion, chest pain, or other urgent symptoms rather than waiting for an integration appointment.

Sources

• JAMA Network Open: Psilocybin adverse effects review
• NIDA: Health effects and research overview
• FDA: Psychedelic clinical investigation guidance